In an order posted by the U.S. Court of Appeals for the Federal Circuit, the court affirmed a win for Amneal Pharmaceuticals (AMRX) in a

Five patents related to Teva Pharmaceutical Industries Ltd.’s ProAir HFA asthma inhaler don’t cover the treatment’s active ingredient and must be delisted from the US Food and Drug Administration’s registry of approved drugs,

Decision vindicates previous FTC actions to promote affordable drugs, generic competition Today, the U.S. Court of Appeals for the Federal Circuit affirmed a lower district court order against pharmaceutical maker Teva requiring the drugmaker to delist several asthma inhaler patents from the Food and Drug Administration's (FDA) Orange Book.